H.C. Wainwright analyst Joseph Pantginis maintained a Hold rating on Onconova Therapeutics (ONTX – Research Report) today. The company’s shares closed last Thursday at $2.80, close to its 52-week low of $2.72.
According to TipRanks.com, Pantginis has 0 stars on 0-5 stars ranking scale with an average return of -5.3% and a 29.7% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Actinium Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Onconova Therapeutics with a $11.00 average price target.
Based on Onconova Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $57K and GAAP net loss of $3.45 million. In comparison, last year the company earned revenue of $66K and had a GAAP net loss of $6.24 million.
Based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ONTX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA.
Read More on ONTX: